ARAV Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 saus. 2024 @ 23:00):

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...

Stats
Šios dienos apimtis	4.04M
Vidutinė apimtis	2.24M
Rinkos kapitalizacija	2.95M
EPS	$0 ( 2024-03-20 )
Kita pelno data	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0528
ATR14	$0.0130 (32.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-10	Petrini Maria Carolina	Buy	400 000	Nonqualified Stock Option (Right to Buy)
2023-04-10	Petrini Maria Carolina	Buy	0
2023-02-01	Mcintyre Gail Frances	Buy	700 000	Stock Option (Right to Buy)
2023-02-01	Geller Robert B.	Buy	400 000	Stock Option (Right to Buy)
2023-02-01	Howard Rudy	Buy	400 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 72 486 477 \| Sell: 119 333

Tūris Koreliacija

Ilgas: 0.29 (neutral)

Trumpas: 0.00 (neutral)

Signal:(20.648) Neutral

Aravive Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ALXN	0.865
GENQ	0.848
BMAQ	0.847
ATNX	0.845
ROIV	0.843
TCMD	0.84
FXCO	0.84
OTEC	0.839
BRAC	0.839
ACAB	0.838

10 Labiausiai neigiamai susiję koreliacijos
EPSN	-0.867
GRIN	-0.853
MDGS	-0.853
FJP	-0.843
RFDI	-0.841
EWJV	-0.84
ALKS	-0.84
RNEM	-0.839
IFV	-0.837
PIII	-0.835

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aravive Inc Koreliacija - Valiuta/Žaliavos

-0.19
( neutral )

-0.43
( neutral )

-0.35
( neutral )

-0.72
( moderate negative )

-0.50
( weak negative )

0.30
( neutral )

Aravive Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$9.14M
Bruto pelnas:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2022
Pajamos:	$9.14M
Bruto pelnas:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.48

FY	2020
Pajamos:	$5.69M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.